AI Article Synopsis
- Idiopathic pulmonary fibrosis (IPF) is characterized by specific clinical and imaging criteria, including a pattern known as usual interstitial pneumonia and symptoms like exercise-related breathing difficulties in older adults.
- The incidence of IPF is rising, with identified risk factors such as smoking and dust exposure, yet the exact cause remains a mystery.
- There are no effective treatments currently available, as corticosteroids and immunosuppressants do not help, although therapeutic trials are ongoing.
Article Abstract
Idiopathic pulmonary fibrosis (IPF) is currently defined by a set of histopathological-radiological-clinical criteria including an histopathological pattern of usual interstitial pneumonia, reticular opacities with honeycombing at tomodensitometry, progressive exercise dyspnea in a patient older than 60 years with fine crackles at lung bases at auscultation. The incidence of IPF is increasing. Risk factors for the disease have been identified (smoking, exposure to various dusts, genetic polymorphism) but the true cause of FPI remains unknown. Progression to death within 2-4 years may be accelerated by acute exacerbation which may cause death. There is no efficient treatment for IPF. Corticosteroids and immunosuppressors are of no benefit. Therapeutic trials are on the way.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!